Immunotech Biopharm Ltd
Company Profile
Business description
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
Contact
No.1 Kangding Street
8th Floor, Block 1, Guosheng Technology Park
Beijing Economic-technological Development Area
Beijing100176
CHNT: +86 8610884002
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
173
Stocks News & Analysis
stocks
Fair value downgraded for ASX heavyweight
stocks
ChatGPT enters the retail space and one company surges
stocks
Alibaba fair value increases by 49%
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,136.60 | 15.10 | 0.17% |
CAC 40 | 7,895.94 | 15.07 | 0.19% |
DAX 40 | 23,880.72 | 135.66 | 0.57% |
Dow JONES (US) | 46,397.89 | 81.82 | 0.18% |
FTSE 100 | 9,350.43 | 50.59 | 0.54% |
HKSE | 26,855.56 | 232.68 | 0.87% |
NASDAQ | 22,660.01 | 68.86 | 0.30% |
Nikkei 225 | 44,550.85 | 381.78 | -0.85% |
NZX 50 Index | 13,433.99 | 141.63 | 1.07% |
S&P 500 | 6,688.46 | 27.25 | 0.41% |
S&P/ASX 200 | 8,845.70 | 12.30 | 0.14% |
SSE Composite Index | 3,882.78 | 20.25 | 0.52% |